Orchard Therapeutics plc

Orchard Therapeutics plc is a leading biotechnology company based in the UK, dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Founded in 2015, the company focuses on developing and commercializing advanced therapies that address the underlying causes of genetic disorders.

With a robust pipeline of product candidates, Orchard Therapeutics aims to provide effective treatment options for conditions such as metachromatic leukodystrophy (MLD) and other inherited metabolic disorders. The company’s proprietary platform leverages cutting-edge science and technology to create transformative therapies that can potentially cure these debilitating diseases.

Orchard Therapeutics is committed to patient-centric approaches, ensuring that the needs and experiences of patients and their families are at the forefront of its research and development efforts. The company collaborates with leading academic institutions and industry partners to advance its mission and expand access to its therapies.

Core Values:

• Innovation: Continuously pushing the boundaries of science to develop groundbreaking therapies.
• Collaboration: Working together with stakeholders to enhance the development and delivery of treatments.
• Integrity: Upholding the highest ethical standards in all aspects of the business.
• Patient Focus: Prioritizing the needs and well-being of patients in every decision made.

Headquartered in London, Orchard Therapeutics is strategically positioned to leverage the vibrant biotech ecosystem in the UK. The company is publicly traded and actively engages with investors to support its growth and innovation initiatives.

As it continues to expand its portfolio, Orchard Therapeutics remains steadfast in its vision to redefine the treatment landscape for rare diseases, ultimately aiming to make a meaningful difference in the lives of patients worldwide.